系统性红斑狼疮患者中特异性抗核抗体动态差异及其对B细胞靶向治疗的易感性
该研究分析系统性红斑狼疮(SLE)患者特异性抗核抗体的血清转换与滴度动态,并评估其对利妥昔单抗和贝利尤单抗治疗的反应。结果显示抗Sm/RNP与抗dsDNA类似,较抗SS-A/SS-B更频繁波动,且B细胞靶向治疗后抗dsDNA和抗Sm/RNP滴度下降幅度相当,但仅抗dsDNA下降与临床结局相关。
要点
- 抗Sm和抗RNP较抗SS-A/SS-B更频繁发生血清转换。
- 抗Sm/RNP和抗dsDNA滴度显著波动,而抗SS-A/SS-B滴度稳定。
- B细胞靶向治疗后仅抗dsDNA滴度下降与临床结局相关。
核心结论
- 抗Sm/RNP和抗dsDNA与抗SS-A/SS-B不同,频繁波动且B细胞靶向治疗后水平可下降,提示不同抗核抗体动力学各异,可能反映其来源于不同B细胞分化途径。
研究设计与样本
- 利用SLE患者电子健康记录分析特异性抗核抗体的血清转换。
- 在纵向SLE患者队列的血清样本及接受利妥昔单抗和贝利尤单抗治疗的SLE患者血清中测定特异性抗核抗体和抗水痘-带状疱疹病毒(VZV)抗体滴度。
主要发现
- 抗Sm和抗RNP与抗dsDNA类似,较抗SS-A/SS-B更频繁发生血清转换。
- 抗Sm/RNP和抗dsDNA滴度较稳定的抗VZV对照显著波动,而抗SS-A/SS-B滴度无显著波动。
- B细胞清除治疗后抗dsDNA和抗Sm/RNP滴度下降幅度相当。
- 仅抗dsDNA滴度下降与临床结局相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The presence of antinuclear antibodies (ANAs) is characteristic for systemic lupus erythematosus (SLE). Antibody dynamics over time are thought to reflect the cellular source of ANAs and their therapeutic targetability. Anti-double-stranded DNA (anti-dsDNA) is the most prevalent and well-studied of all ANAs, and fluctuations in anti-dsDNA serum levels are associated with disease activity. Antibody dynamics of other ANAs, such as antibodies targeting RNA-binding proteins (RBPs), are often considered more stable compared to anti-dsDNA. However, anti-RBPs may be heterogeneous in nature, and their fluctuation has not been extensively analyzed. Therefore, we aimed to study the dynamics of the different ANAs and their susceptibility to B cell-targeting treatments in patients with SLE. METHODS: Seroconversion of specific ANAs was analyzed using electronic health records from patients with SLE. Titers of specific ANAs and anti-varicella zoster virus (VZV) were determined in serum samples from a longitudinal cohort of patients with SLE and serum from patients with SLE treated with rituximab and belimumab. RESULTS: Anti-Smith (anti-Sm) and anti-RNP, similar to anti-dsDNA titers, seroconverted more frequently compared to anti-SS-A/SS-B. Furthermore, anti-Sm/RNP and anti-dsDNA titers, but not anti-SS-A/SS-B titers, fluctuated significantly compared to stable anti-VZV controls. Likewise, reductions in anti-dsDNA and anti-Sm/RNP titers after B cell-depleting treatment were comparable in magnitude. However, only anti-dsDNA titer reductions associated with clinical outcomes. CONCLUSION: Together, these results show that anti-Sm/RNP and anti-dsDNA, in contrast to anti-SS-A/SS-B, frequently fluctuate and their levels can decrease following B cell-targeted treatments. Thus, distinct ANAs have variable kinetics, potentially reflecting their derivation from different B cell differentiation pathways.
引用
- van Dooren HJ, van Schaik M, Dorjée AL, et al. Differences in Dynamics of Specific Antinuclear Antibodies and Their Susceptibility to B Cell-Targeting Treatment in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2025. PMID: 40356198. doi:10.1002/art.43219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。